Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Keros Therapeutics, Inc. (NASDAQ: KROS)
KROS Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
202.60%
Analyst Rating:
BUY
Analyst Forecast (1yr):
101.90%
KROS Stock Analysis
KROS
PE Ratio:
KROS
PEG Ratio:
Not Available
KROS
Forward EPS Growth (12 month):
0.00%
KROS
PS Ratio:
10.1
KROS
PSG Ratio:
KROS
Forward Revenue Growth (12 month):
221.30%
KROS Articles
No data was found